| Patricia Deann Copley, MD | |
|
1602 Rock Prairie Rd, Suite 2400, College Station, TX 77845-8306 | |
| (979) 694-1300 | |
| (979) 694-1313 |
| Full Name | Patricia Deann Copley |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 28 Years |
| Location | 1602 Rock Prairie Rd, College Station, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619912979 | NPI | - | NPPES |
| 096549303 | Medicaid | TX | |
| P00270721 | Other | TN | RR MEDICARE PIN |
| 3859838 | Medicaid | TN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Deaconess Hospital Inc | Evansville, IN | Hospital |
| Valley View Hospital Association | Glenwood springs, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Deaconess Hospital Inc | 9032021431 | 308 |
| Montrose Memorial Hospital Inc | 1658272992 | 61 |
| Valley View Hospital Association | 1850294778 | 167 |
News Archive
An international team of researchers led by Huntsman Cancer Institute at the University of Utah has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease.
A study in mice conducted by the UAB shows that social isolation worsens the effects of Alzheimer's disease, with hyperactivity levels reaching up to twice as much as in the pathology itself.
Nine researchers, working on innovative projects that promise to improve healthcare diagnosis and treatment, across a wide spread of issues, were today announced as the first recipients of the Engineering and Physical Sciences Research Council's (EPSRC) Healthcare Technologies Challenge Awards.
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.
› Verified 7 days ago
| Entity Name | Parkview Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932130952 PECOS PAC ID: 2163336967 Enrollment ID: O20031117000288 |
News Archive
An international team of researchers led by Huntsman Cancer Institute at the University of Utah has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease.
A study in mice conducted by the UAB shows that social isolation worsens the effects of Alzheimer's disease, with hyperactivity levels reaching up to twice as much as in the pathology itself.
Nine researchers, working on innovative projects that promise to improve healthcare diagnosis and treatment, across a wide spread of issues, were today announced as the first recipients of the Engineering and Physical Sciences Research Council's (EPSRC) Healthcare Technologies Challenge Awards.
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.
› Verified 7 days ago
| Entity Name | Deaconess Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427097443 PECOS PAC ID: 9032021431 Enrollment ID: O20040115000129 |
News Archive
An international team of researchers led by Huntsman Cancer Institute at the University of Utah has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease.
A study in mice conducted by the UAB shows that social isolation worsens the effects of Alzheimer's disease, with hyperactivity levels reaching up to twice as much as in the pathology itself.
Nine researchers, working on innovative projects that promise to improve healthcare diagnosis and treatment, across a wide spread of issues, were today announced as the first recipients of the Engineering and Physical Sciences Research Council's (EPSRC) Healthcare Technologies Challenge Awards.
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.
› Verified 7 days ago
| Entity Name | Good Samaritan Hospital Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649432071 PECOS PAC ID: 3971671330 Enrollment ID: O20081013000182 |
News Archive
An international team of researchers led by Huntsman Cancer Institute at the University of Utah has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease.
A study in mice conducted by the UAB shows that social isolation worsens the effects of Alzheimer's disease, with hyperactivity levels reaching up to twice as much as in the pathology itself.
Nine researchers, working on innovative projects that promise to improve healthcare diagnosis and treatment, across a wide spread of issues, were today announced as the first recipients of the Engineering and Physical Sciences Research Council's (EPSRC) Healthcare Technologies Challenge Awards.
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.
› Verified 7 days ago
| Entity Name | Select Specialty Hospital - Evansville Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750380739 PECOS PAC ID: 9830295864 Enrollment ID: O20120213000034 |
News Archive
An international team of researchers led by Huntsman Cancer Institute at the University of Utah has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease.
A study in mice conducted by the UAB shows that social isolation worsens the effects of Alzheimer's disease, with hyperactivity levels reaching up to twice as much as in the pathology itself.
Nine researchers, working on innovative projects that promise to improve healthcare diagnosis and treatment, across a wide spread of issues, were today announced as the first recipients of the Engineering and Physical Sciences Research Council's (EPSRC) Healthcare Technologies Challenge Awards.
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patricia Deann Copley, MD Po Box 689022, Franklin, TN 37068-9022 Ph: (615) 465-7635 | Patricia Deann Copley, MD 1602 Rock Prairie Rd, Suite 2400, College Station, TX 77845-8306 Ph: (979) 694-1300 |
News Archive
An international team of researchers led by Huntsman Cancer Institute at the University of Utah has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease.
A study in mice conducted by the UAB shows that social isolation worsens the effects of Alzheimer's disease, with hyperactivity levels reaching up to twice as much as in the pathology itself.
Nine researchers, working on innovative projects that promise to improve healthcare diagnosis and treatment, across a wide spread of issues, were today announced as the first recipients of the Engineering and Physical Sciences Research Council's (EPSRC) Healthcare Technologies Challenge Awards.
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.
› Verified 7 days ago
Joseph Jason Roman, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1602 Rock Prairie Rd, Suite 4880, College Station, TX 77845 Phone: 979-796-1111 Fax: 979-764-1164 | |
Ashley Annly Liou, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 700 Scott And White Dr, College Station, TX 77845 Phone: 979-207-0100 Fax: 979-207-2161 | |
Rajpreet Kaur Singh, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1725 Birmingham Rd Ste 200, College Station, TX 77845 Phone: 979-696-8000 Fax: 979-696-8100 | |
Dr. Natraj Aiyappan Shanmugam, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1602 Rock Prairie Rd, Suite 210, College Station, TX 77845 Phone: 979-696-5663 Fax: 979-694-1319 | |
Kaycee Leigh Weaver, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 700 Scott And White Dr, College Station, TX 77845 Phone: 979-207-0100 | |
Dr. Daniel Philip Stagg Iii, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Scott And White Dr, College Station, TX 77845 Phone: 979-207-4000 Fax: 979-207-4562 | |
Dr. Thomas H. Meade, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1721 Birmingham Rd Ste 202, College Station, TX 77845 Phone: 979-446-0373 |